The Mid-Size Pharmaceutical Market: Market Assessment, Growth Forecasts and Strategic Consolidations for Key Players

  • ID: 4575990
  • Report
  • Region: Global
  • 140 Pages
  • CBR Pharma Insights
1 of 5
The Worldwide Pharmaceutical Market is Projected to Grow from Approximately $1.1 Trillion in 2016 to $1.5 Trillion in 2021

FEATURED COMPANIES

  • Alexion Pharmaceuticals
  • Eisai
  • Horizon Pharma
  • Intas Pharmaceuticals
  • Les Laboratories Servier
  • Regeneron Pharmaceuticals
  • MORE

Summary

The worldwide pharmaceutical market is projected to grow from approximately $1.1 trillion in 2016 to $1.5 trillion in 2021, representing a compound annual growth rate of 6.4%. The ten major developed markets are expected to cover 67% of global spending by 2021, which is 1% less than their share in 2016. Growth will be driven by global demographic and economic trends, including a rapidly aging global population and an associated rise in chronic diseases; increased urbanization; higher disposable income; greater government expenditure on healthcare; and growing demand for more effective treatments.

The pharmaceutical sector can be divided into various categories based on revenue, comprising large, mid-size and small pharma companies. The mid-size sector, which is the focus of this report, consists of 82 companies with revenue ranging from $1 billion to $10 billion, while small and large companies fall below and above this threshold, respectively.

Most mid-size pharma companies are focusing heavily on developing a portfolio of generic products covering a variety of therapy areas and geographies. Additionally, the top mid-size companies are involved in the end-to-end development of innovative products, although in these cases their focus is limited to specific therapy areas.

A few mid-size companies diverge from the typical trends and are particularly focused on rare diseases, such as the Alexion Pharmaceuticals. In these ways mid-size companies can be seen to be different to large pharma companies, which almost all focus on end-to-end product development covering a variety of therapy areas and geographies. Large pharma companies have sufficient investment capability and human resources to support a wider variety of R&D activities than mid-size pharma.

The report ""The Mid-Size Pharmaceutical Market: Market Assessment, Growth Forecasts and Strategic Consolidations for Key Players"" focuses on comparative analysis of mid-size pharma companies and the strategies followed in order to sustain and grow in the market, from data covering over 80 mid-size companies both those focused exclusively on pharma, and those also involved in other divisions of healthcare, such as medical devices, in addition to pharma products.

Companies mentioned Daiichi Sankyo, Valeant Pharmaceuticals, Eisai, Regeneron Pharmaceuticals, UCB, Les Laboratories Servier, Sun Pharmaceutical, Endo International, Mallinckrodt, Kyowa Hakko Kirin, Alexion Pharmaceuticals, Taisho Pharmaceutical.

Scope

  • How can the mid-sized pharma segment be defined in general, and what is its role in the industry?
  • Which mid-size pharma companies are on the leaders in terms of revenue, R&D expenditure, number of R&D products, marketed products and number of employees in 2016?
  • What is the revenue forecast for the key mid-size companies in 2023?
  • What are the key marketed products of the top mid-size pharma companies? What were the global sales figures in 2016 and what are the forecasts for 2023 for these products?
  • Which therapy areas are the key mid-size companies are focusing on? What are the global sales forecasts of late-stage pipeline products that are set to enter the market during the forecast period?
  • What was the year-on-year revenue growth and year-on-year R&D expenditure of key mid-size pharma companies between 2014 and 2016?
  • What are the key strategies followed by mid-size pharma companies to improve their revenue and push towards joining the large pharma segment?
  • What are the key challenges faced by mid-size pharma companies?

Reasons to buy

  • Interpret the key players in the mid-size pharma segment through the analysis of companies, particularly based on R&D investments, year-on-year revenue and R&D expenditure, and pipeline and marketed products.
  • Gain insights on how mid-size pharma companies have explored new technologies to shape their current portfolios and R&D pipelines.
  • Understand the detailed profiling of top mid-size pharma companies based on their revenue in 2016. The profiling of the companies includes top-selling marketed products, major late-stage pipeline products expected to enter into the market in the near future and their forecasts, and key deals analysis.
  • Recognize the various challenges faced by mid-size pharma companies.
  • Understand the major growth strategies followed by mid-size pharma companies in recent years.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Alexion Pharmaceuticals
  • Eisai
  • Horizon Pharma
  • Intas Pharmaceuticals
  • Les Laboratories Servier
  • Regeneron Pharmaceuticals
  • MORE

1. Introduction

  • What is the Mid-Sized Pharma Segment and What is its Role in the Industry?
  • Why is Mid-size Pharma a Key Element of the Industry?

2. Mid-size Pharma Players with Revenue Forecasts

  • Comparative Analysis and Ranking - Based on Revenue
  • R&D Expenditure
  • Number of Pipeline Products
  • Number of Marketed Products
  • Number of Employees
  • Location of Headquarter
  • Year-on-Year Revenue
  • Year-on-Year R&D Expenditure

3. Key Points

  • Mid-size Pharma Companies - Growth Strategies related to Deals and Collaborations
  • Mergers and Acquisitions
  • Licensing Agreements and Partnerships
  • R&D Collaboration
  • Geographical Expansion
  • In-House Research and Development
  • Shift towards High-Value Generics from Low-Value Generics
  • Brand Building
  • Specialized Therapy Areas and Rare Diseases

4. Top Mid-size Pharma Companies

  • Daiichi Sankyo
  • Valeant Pharmaceuticals
  • Eisai
  • Regeneron Pharmaceuticals
  • UCB
  • Les Laboratories Servier
  • Sun Pharmaceutical
  • Endo International
  • Mallinckrodt
  • Kyowa Hakko Kirin
  • Alexion Pharmaceuticals
  • Taisho Pharmaceutical

5. Overview

  • Top Marketed Products
  • Pipeline Overview
  • Late stage Products with Sales Forecast
  • Revenue Forecast
  • Deals by Value and Volume
  • Key Deals

6. Top Small Pharma Companies Likely to Enter the Mid-size Segment

  • Horizon Pharma
  • Intas Pharmaceuticals
  • Hypermarcas

7. Challenges Faced by Mid-size Pharma

8. Conclusion

9. List of Mid-size Pharma Companies

10. Bibliography

  • Disclaimer
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Alexion Pharmaceuticals
  • Daiichi Sankyo
  • Eisai
  • Endo International
  • Horizon Pharma
  • Hypermarcas
  • Intas Pharmaceuticals
  • Kyowa Hakko Kirin
  • Les Laboratories Servier
  • Mallinckrodt
  • Regeneron Pharmaceuticals
  • Sun Pharmaceutical
  • Taisho Pharmaceutical
  • UCB
  • Valeant Pharmaceuticals
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll